Biomarin Pharmaceutical Inc
BMRN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001048477
In the last 90 days, Biomarin Pharmaceutical Inc insiders filed 0 open-market purchases and 1 sale; 565 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q4 2022
Institutional positions in Biomarin Pharmaceutical Inc as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 581
- +40 vs. Q3 2022
- Shares held
- 182.9M
- +771.4K (+0.4%) vs. Q3 2022
- Total value
- $18.9B
- +$3.49B (+22.6%) vs. Q3 2022
- New holders
- 88
- 199 more added
- Sold out
- 48
- 206 more reduced
11 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BMRN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 565 | $11.1B |
| Q1 2026 | 559 | $10.4B |
| Q4 2025 | 539 | $11.2B |
| Q3 2025 | 577 | $9.72B |
| Q2 2025 | 582 | $10.1B |
| Q1 2025 | 584 | $13.0B |
| Q4 2024 | 544 | $12.0B |
| Q3 2024 | 556 | $12.7B |
| Q2 2024 | 561 | $15.2B |
| Q1 2024 | 560 | $16.3B |
| Q4 2023 | 549 | $17.9B |
| Q3 2023 | 521 | $16.1B |
| Q2 2023 | 559 | $15.5B |
| Q1 2023 | 554 | $17.4B |
| Q4 2022 | 581 | $18.9B |
| Q3 2022 | 552 | $15.5B |
| Q2 2022 | 544 | $14.8B |
| Q1 2022 | 560 | $13.7B |
| Q4 2021 | 557 | $15.7B |
| Q3 2021 | 514 | $13.6B |
| Q2 2021 | 531 | $14.7B |
| Q1 2021 | 532 | $13.5B |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Biomarin Pharmaceutical Inc; share changes are against Q3 2022.